RSV Pre-Fusion F Glycoprotein mRNA Vaccine
This is an mRNA-based vaccine designed to prevent Respiratory Syncytial Virus (RSV) infection by targeting the pre-fusion F glycoprotein, a key surface protein of the virus. It is primarily intended for older adults (60 years and above) and some formulations for infants, as these populations are at highest risk for severe RSV disease including bronchiolitis and pneumonia. The vaccine leverages mRNA technology to instruct cells to produce the viral antigen, triggering an immune response without causing infection.
An mRNA vaccine that protects against Respiratory Syncytial Virus (RSV) by targeting the pre-fusion F glycoprotein, primarily used in older adults and high-risk populations.
Key facts at a glance
- RxNorm
- 2685002
- Generic
- Respiratory Syncytial Virus Pre-Fusion F Glycoprotein Mrna
- Class
- unclassified
- Brands
- Mresvia
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of Respiratory Syncytial Virus (RSV) infection in adults 60 years of age and older, and in some cases, maternal immunization to protect infants. It helps reduce the risk of lower respiratory tract disease caused by RSV, including bronchiolitis and pneumonia.
The vaccine contains mRNA that encodes the RSV pre-fusion F glycoprotein, a stabilized form of the virus's fusion protein. After injection, cells produce this viral protein, which prompts the immune system to generate neutralizing antibodies and cellular immune responses against RSV.
Common side effects may include injection site pain, fatigue, headache, and muscle aches. As with other mRNA vaccines, allergic reactions are possible. The vaccine does not contain live virus and cannot cause RSV infection. Efficacy and safety data continue to be monitored through post-marketing surveillance.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 29, 2026. · Read our editorial policy